-

02:19:46 PM

CLNN Stock News

CLNN - Clene Inc

09/28/23 8:00 AM

Nasdaq : CLNN

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine

RHEA-AI

neutral

09/25/23 4:00 PM

Nasdaq : CLNN

conferences

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function

RHEA-AI

neutral

09/25/23 7:00 AM

Nasdaq : CLNN

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 ® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046 Prolonged life with 59% decreased risk of death for participants in an integrated meta-analysis across

RHEA-AI

neutral

08/30/23 8:20 AM

Nasdaq : CLNN

conferences

Clene to Present at Upcoming September Conferences

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to

RHEA-AI

neutral

08/29/23 7:00 AM

Nasdaq : CLNN

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

RHEA-AI

neutral

08/14/23 8:00 AM

Nasdaq : CLNN

earnings

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8 ® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and its open-label

RHEA-AI

neutral

08/02/23 7:00 AM

Nasdaq : CLNN

conferences

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today

RHEA-AI

neutral

06/26/23 8:00 AM

Nasdaq : CLNN

clinical trial

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary

RHEA-AI

neutral

06/21/23 9:20 AM

Nasdaq : CLNN

offering

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Investment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40 million underwritten public offering with up to an additional potential $130.8 million in proceeds

RHEA-AI

neutral

06/16/23 8:00 AM

Nasdaq : CLNN

offering

Clene Announces Pricing of $40 Million Public Offering

Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next